Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CPHbiomedix ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   0.0% 0.0% 0.0% 3.1% 3.0% 2.5% 8.1% 7.8%   Credit score (0-100)   0 0 0 56 56 62 30 31   Credit rating   N/A N/A N/A BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 0.0 0.0 1,342 1,292 1,139 0.0 0.0   EBITDA   0.0 0.0 0.0 571 520 465 0.0 0.0   EBIT   0.0 0.0 0.0 411 360 305 0.0 0.0   Pre-tax profit (PTP)   0.0 0.0 0.0 402.8 358.9 304.5 0.0 0.0   Net earnings   0.0 0.0 0.0 313.9 279.5 237.5 0.0 0.0   Pre-tax profit without non-rec. items   0.0 0.0 0.0 403 359 305 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   0.0 0.0 0.0 3,060 3,340 3,577 3,537 3,537   Interest-bearing liabilities   0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0   Balance sheet total (assets)   0.0 0.0 0.0 3,305 3,581 3,789 3,537 3,537   Net Debt   0.0 0.0 0.0 -179 -719 -593 -2,417 -2,417     See the entire balance sheet 1000.0 Volume  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 0.0 1,342 1,292 1,139 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 0.0% -3.7% -11.9% -100.0% 0.0%   Employees   0 0 0 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   0 0 0 3,305 3,581 3,789 3,537 3,537   Balance sheet change%   0.0% 0.0% 0.0% 0.0% 8.4% 5.8% -6.6% 0.0%   Added value   0.0 0.0 0.0 570.9 520.3 464.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 1,280 -320 -320 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   0.0 0.0 0.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 0.0% 30.6% 27.9% 26.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   0.0% 0.0% 0.0% 12.4% 10.5% 8.3% 0.0% 0.0%   ROI %   0.0% 0.0% 0.0% 13.4% 11.3% 8.8% 0.0% 0.0%   ROE %   0.0% 0.0% 0.0% 10.3% 8.7% 6.9% 0.0% 0.0%   1000.0 Solidity  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   0.0% 0.0% 0.0% 92.6% 93.3% 94.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% 0.0% 0.0% -31.3% -138.2% -127.7% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 4,552.0% 321.4% 76.0% 0.0% 0.0%   1000.0 Liquidity  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   0.0 0.0 0.0 7.6 9.5 12.5 0.0 0.0   Current Ratio   0.0 0.0 0.0 7.6 9.5 12.5 0.0 0.0   Cash and cash equivalent   0.0 0.0 0.0 179.0 719.4 593.4 0.0 0.0   1000.0 Capital use efficiency  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   0.0 0.0 0.0 1,612.0 2,050.4 2,447.8 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 N/A 2020 N/A 2021 N/A 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 571 520 465 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 571 520 465 0 0   EBIT / employee   0 0 0 411 360 305 0 0   Net earnings / employee   0 0 0 314 279 237 0 0